Vascular endothelial growth factor in angiosarcoma

Anticancer Research

Volumn 18, Issue 5 B, 1998, Pages 3725-3729

  Fujimoto, Mitsuo ^a   Kiyosawa, Tomoharu ^a   Murata, Satoru ^a   Matsuo, Katsuhiko ^a   Suzuki, Hideo ^a   Sone, Hirohito ^a   Okuda, Yukichi ^a   Nakayama, Yoshio ^a   Yaoita, Hideo ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Angiosarcoma; ELISA; VEGF

Indexed keywords

C REACTIVE PROTEIN; MITOGENIC AGENT; VASCULOTROPIN;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; BENIGN TUMOR; BLOOD LEVEL; CASE REPORT; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TUMOR GROWTH; VASCULAR LESION;

EID: 0031675547     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Mark RJ, Tran LM, Sercarz J et al: Angiosarcoma of the head and neck. The UCLA experience 1955 through 1990. Arch Otolaryngol Head Neck Surg 119: 973-978, 1993.
2. Naka N, Ohsawa M, Tomita Y et al: Angiosarcoma in Japan. A review of 99 cases. Cancer 75(4): 989-996, 1994.
3. Lydiatt WM, Shara AR, Shah JP et al: Angiosarcoma of the head and neck. Am J Surg 168: 451-454, 1994.
4. Krasagakis K, Hettmannsperger U, Tebbe B et al: Cutaneous metastatic angiosarcoma with a lethal outcome, following radiotherapy for a cervical carcinoma. Br J Dermatol 133: 610-614, 1995.
5. Ferrara N, Houck K, Jakeman L et al: Molecular and biological properties of the vascular endothelial growth gactor family of proteins. Endocrine Rev 13(1): 18-32, 1992.
6. Ferrara N, Houck K, Jakeman L et al: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47: 211-218, 1991.
7. Dvorak H, Brown L, Detmar M et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146(5): 1029-1039, 1995.
8. Hanatani M, Tanaka Y, Kondo S et al: Sensitive chemiluminescence enzyme immunoassay for vascular endothelial growth factor/vascular permeability factor in human serum. Biosci Biotech Biochem 59(10): 1958-1959, 1995.
9. Yamamoto Y, Toi M, Kondo S et al: Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2: 821-826, 1996.
10. Rosenberg SA, Lotze MT, Muul LM et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Eng J Med 316: 889-897, 1987.
11. Rosenberg SA, Lotze MT, Muul LM et al: Observations of the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 313: 1485-1491, 1985.
12. Damle NK, Doyle LV, Bender JR et al: Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 138: 1779-1785, 1987.
13. Masuzawa M, Hasegawa H, Tajiri K et al. Successful immunotherapy for malignant hemangioendothelioma using recombinant interleukin-2[in Japanese]. Jpn J Dermatol 98: 367-369, 1988.
14. Furue M, Yamada N, Takahashi T et al: Immunotherapy for Stewart-Treves syndrome. Usefulness of intrapleural administration of tumor-infiltrating lymphocytes against massive pleural effusion caused by metastatic angiosarcoma. J Am Acad Dermatol 30(5pt2): 899-903, 1994.
15. Froment O, Marion MJ, Lepot D et al: Immunoquantitation of Von Willebrand factor(factor VIII-related antigen) in vinyl chloride exposed workers. Cancer Lett 61(3): 201-206, 1992.
16. Hodak E, Trattner A, David M et al: Quantitative and qualitative assessment of plasma von Willebrand factor in classic Kaposi's sarcoma. J Am Acad Dermatol 28(2pt1): 217-221, 1993.
17. Watanabe K, Hoshi N, Suzuki T et al: Epitheloid angiosarcoma of the intestinal tract with endothelin-1-like immunoreactivity. Virchows Arch A Pathl Anat Histopathol 423(4): 309-314, 1993.
18. Yokokawa K, Tahara H, Kohno M et al: Hypertension associated endothelin-secreting malignant hemangioendothelioma. Ann Int Med 114: 213-215, 1991.
19. Fujimoto K, Ichimori Y, Kakizoe T et al: Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun 180(1): 386-392, 1991.
20. Nguyen M, Watanabe H, Budson AE et al: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 85: 241-242, 1993.
21. Nguyen M, Watanabe H, Budson AE et al: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86: 356-361, 1994.
22. Kondo S, Asano M, Matsuo K et al: Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1221: 211-214, 1994.
23. Morii K, Tanaka R, Washiyama K et al: Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Commun 194(2): 749-755, 1993.
24. Bohling T, Hatva E, Kujila M et al: Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J Neuropathol Exp Neurol 55(5): 522-527, 1996.
25. Hashimoto M, Ohsawa M, Ohnishi A et al: Expression of vascular endothelial growth factor and its receptor mRNA in Angiosarcoma. Lab Invest 73(6): 859-863, 1995.
26. Yeo KT, Wang HH, Nagy JA et al: Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusion. Cancer Res 53: 2912-2918, 1993.
27. Toi M, Kondo S, Suzuki H et al: Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77(6): 1101-1106, 1996.
28. Brown LF, Tognazzi K, Dvorak HF et al: Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 148(4): 1065-1074, 1996.